-
公开(公告)号:NO922530A
公开(公告)日:1992-12-28
申请号:NO922530
申请日:1992-06-26
Applicant: GLAXO INC
Inventor: MYERS PETER LESLIE , MCELROY ANDREW BRIAN , GREGSON MICHAEL , BROWN PETER JONATHAN , DAVIES HOWARD GEOFFREY , DREWRY DAVID HAROLD , FOLEY MICHAEL ANDREW
IPC: A61K38/55 , A61K38/00 , A61P1/02 , A61P17/00 , A61P19/10 , A61P25/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D209/48 , C07D209/66 , C07D471/04 , C07D471/14 , C07D487/04 , C07D487/14 , C07K1/06 , C07K1/113 , C07K5/02 , C07K5/06 , C07K5/08 , A61K37/64 , C07K5/10
CPC classification number: C07K5/0222 , A61K38/00
-
公开(公告)号:IE922083A1
公开(公告)日:1992-12-30
申请号:IE922083
申请日:1992-07-01
Applicant: GLAXO INC
Inventor: MYERS PETER LESLIE , MCELROY ANDREW BRIAN , GREGSON MICHAEL , BROWN PETER JOHNATHAN , DAVIES HOWARD GEOFFREY , DREWRY DAVID HORLEY , FOLEY MICHAEL ANDREW
IPC: A61K38/55 , A61K38/00 , A61P1/02 , A61P17/00 , A61P19/10 , A61P25/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D209/48 , C07D209/66 , C07D471/04 , C07D471/14 , C07D487/04 , C07D487/14 , C07K1/06 , C07K1/113 , C07K5/02 , C07K5/06 , C07K5/08 , C07K5/00
Abstract: Compounds are described of the formula wherein: R is C3-6alkyl or C1-3alkylthioC1-3alkyl; R is an optionally substituted C1-6alkyl or C1-6alkoxy group, aryl, heteroaryl, arylC1-4alkyl, heteroarylC1-4alkyl or a side-chain of a natural alpha -amino acid; R is hydrogen, C1-6alkyl, CHR COR (where R is a side-chain of a natural alpha -amino acid and R is hydroxyl, C1-6alkoxy or NHR where R represents a hydrogen atom or a C1-6alkyl group) or a group (CH2)nX (where n is 1 to 6 and X is hydroxyl, C1-4alkoxy, heteroaryl or a group NR R where R and R are each hydrogen or C1-6alkyl or the group NR R forms a 5 to 7 membered cyclic amine); and Het is an optionally substituted cyclic imide where the cyclic imide ring system has the formula (i), (ii) or (iii) in which A, B, C and D are each CH or 1 or 2 of A, B, C and D represents N and the others represent CH, and E and F may each independently represent CH or N; and physiologically acceptable salts and solvates thereof. These compounds inhibit metalloproteases involved in tissue degradation. Compounds of the invention may be formulated for use in a variety of conditions involving tissue degradation including arthropathy, dermatological conditions, bone resorption, inflammatory diseases, tumour invasion and multiple sclerosis and related diseases involving myelin degradation, and in the promotion of wound healing.
-
公开(公告)号:NO922530L
公开(公告)日:1992-12-28
申请号:NO922530
申请日:1992-06-26
Applicant: GLAXO INC
Inventor: MYERS PETER LESLIE , MCELROY ANDREW BRIAN , GREGSON MICHAEL , BROWN PETER JONATHAN , DAVIES HOWARD GEOFFREY , DREWRY DAVID HAROLD , FOLEY MICHAEL ANDREW
IPC: A61K38/55 , A61K38/00 , A61P1/02 , A61P17/00 , A61P19/10 , A61P25/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D209/48 , C07D209/66 , C07D471/04 , C07D471/14 , C07D487/04 , C07D487/14 , C07K1/06 , C07K1/113 , C07K5/02 , C07K5/06 , C07K5/08 , C07K5/10 , A61K37/64
Abstract: Compounds are described of the formula wherein: R is C3-6alkyl or C1-3alkylthioC1-3alkyl; R is an optionally substituted C1-6alkyl or C1-6alkoxy group, aryl, heteroaryl, arylC1-4alkyl, heteroarylC1-4alkyl or a side-chain of a natural alpha -amino acid; R is hydrogen, C1-6alkyl, CHR COR (where R is a side-chain of a natural alpha -amino acid and R is hydroxyl, C1-6alkoxy or NHR where R represents a hydrogen atom or a C1-6alkyl group) or a group (CH2)nX (where n is 1 to 6 and X is hydroxyl, C1-4alkoxy, heteroaryl or a group NR R where R and R are each hydrogen or C1-6alkyl or the group NR R forms a 5 to 7 membered cyclic amine); and Het is an optionally substituted cyclic imide where the cyclic imide ring system has the formula (i), (ii) or (iii) in which A, B, C and D are each CH or 1 or 2 of A, B, C and D represents N and the others represent CH, and E and F may each independently represent CH or N; and physiologically acceptable salts and solvates thereof. These compounds inhibit metalloproteases involved in tissue degradation. Compounds of the invention may be formulated for use in a variety of conditions involving tissue degradation including arthropathy, dermatological conditions, bone resorption, inflammatory diseases, tumour invasion and multiple sclerosis and related diseases involving myelin degradation, and in the promotion of wound healing.
-
公开(公告)号:FI922964A
公开(公告)日:1992-12-28
申请号:FI922964
申请日:1992-06-26
Applicant: GLAXO INC
Inventor: MYERS PETER LESLIE , MCELROY ANDREW BRIAN , GREGSON MICHAEL , BROWN PETER JONATHAN , DAVIES HOWARD GEOFFREY , DREWRY DAVID HAROLD , FOLEY MICHAEL ANDREW
IPC: A61K38/55 , A61K38/00 , A61P1/02 , A61P17/00 , A61P19/10 , A61P25/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D209/48 , C07D209/66 , C07D471/04 , C07D471/14 , C07D487/04 , C07D487/14 , C07K1/06 , C07K1/113 , C07K5/02 , C07K5/06 , C07K5/08
Abstract: Compounds are described of the formula wherein: R is C3-6alkyl or C1-3alkylthioC1-3alkyl; R is an optionally substituted C1-6alkyl or C1-6alkoxy group, aryl, heteroaryl, arylC1-4alkyl, heteroarylC1-4alkyl or a side-chain of a natural alpha -amino acid; R is hydrogen, C1-6alkyl, CHR COR (where R is a side-chain of a natural alpha -amino acid and R is hydroxyl, C1-6alkoxy or NHR where R represents a hydrogen atom or a C1-6alkyl group) or a group (CH2)nX (where n is 1 to 6 and X is hydroxyl, C1-4alkoxy, heteroaryl or a group NR R where R and R are each hydrogen or C1-6alkyl or the group NR R forms a 5 to 7 membered cyclic amine); and Het is an optionally substituted cyclic imide where the cyclic imide ring system has the formula (i), (ii) or (iii) in which A, B, C and D are each CH or 1 or 2 of A, B, C and D represents N and the others represent CH, and E and F may each independently represent CH or N; and physiologically acceptable salts and solvates thereof. These compounds inhibit metalloproteases involved in tissue degradation. Compounds of the invention may be formulated for use in a variety of conditions involving tissue degradation including arthropathy, dermatological conditions, bone resorption, inflammatory diseases, tumour invasion and multiple sclerosis and related diseases involving myelin degradation, and in the promotion of wound healing.
-
公开(公告)号:NO922530D0
公开(公告)日:1992-06-26
申请号:NO922530
申请日:1992-06-26
Applicant: GLAXO INC
Inventor: MYERS PETER LESLIE , MCELROY ANDREW BRIAN , GREGSON MICHAEL , BROWN PETER JONATHAN , DAVIES HOWARD GEOFFREY , DREWRY DAVID HAROLD , FOLEY MICHAEL ANDREW
IPC: A61K38/55 , A61K38/00 , A61P1/02 , A61P17/00 , A61P19/10 , A61P25/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D209/48 , C07D209/66 , C07D471/04 , C07D471/14 , C07D487/04 , C07D487/14 , C07K1/06 , C07K1/113 , C07K5/02 , C07K5/06 , C07K5/08 , C07K5/00
Abstract: Compounds are described of the formula wherein: R is C3-6alkyl or C1-3alkylthioC1-3alkyl; R is an optionally substituted C1-6alkyl or C1-6alkoxy group, aryl, heteroaryl, arylC1-4alkyl, heteroarylC1-4alkyl or a side-chain of a natural alpha -amino acid; R is hydrogen, C1-6alkyl, CHR COR (where R is a side-chain of a natural alpha -amino acid and R is hydroxyl, C1-6alkoxy or NHR where R represents a hydrogen atom or a C1-6alkyl group) or a group (CH2)nX (where n is 1 to 6 and X is hydroxyl, C1-4alkoxy, heteroaryl or a group NR R where R and R are each hydrogen or C1-6alkyl or the group NR R forms a 5 to 7 membered cyclic amine); and Het is an optionally substituted cyclic imide where the cyclic imide ring system has the formula (i), (ii) or (iii) in which A, B, C and D are each CH or 1 or 2 of A, B, C and D represents N and the others represent CH, and E and F may each independently represent CH or N; and physiologically acceptable salts and solvates thereof. These compounds inhibit metalloproteases involved in tissue degradation. Compounds of the invention may be formulated for use in a variety of conditions involving tissue degradation including arthropathy, dermatological conditions, bone resorption, inflammatory diseases, tumour invasion and multiple sclerosis and related diseases involving myelin degradation, and in the promotion of wound healing.
-
-
-
-